<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658187</url>
  </required_header>
  <id_info>
    <org_study_id>DM/171201/HGH</org_study_id>
    <nct_id>NCT03658187</nct_id>
  </id_info>
  <brief_title>Assessment of the Acute Effect of IP</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Assess the Acute Effect of IP on hGH Levels in Aging Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a nutraceutical system, consisting of oral tablet and an oral spray called Alpha GPC,
      which helps your body naturally restore the HGH levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Actual">January 25, 2019</completion_date>
  <primary_completion_date type="Actual">October 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the plasma human growth hormone (hGH) levels in aging individuals</measure>
    <time_frame>Pre-dose: 0 hours and Post dose: 30, 60, 90,120 mins</time_frame>
    <description>Change in serum hGH levels from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on Visual Analogue Score for Fatigue</measure>
    <time_frame>From Day 0 to Day 1</time_frame>
    <description>Change in Visual Analogue Scale score in IP and placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Deficiency Growth Hormone</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.</description>
    <arm_group_label>IP</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>IP</intervention_name>
    <description>Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.</description>
    <arm_group_label>IP</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females having age between 40-60 years (both inclusive)

          -  BMI ≥25 and ≤29.9 kg/m2

          -  FBS ≤ 120 mg/dl

          -  Serum hGH levels ≤0.94 ng/ml in females and ≤0.12 in males

          -  Thyroid Stimulating Hormone ≥ 0.35 and ≤ 5.55 mIU/ml

        Exclusion Criteria:

          -  History of thyroid disorder (Hyper/Hypo).

          -  Smokers having at least 1 cigarette per day.

          -  Known hypersensitivity or allergy to one or more of the ingredients of the IP

          -  Participant suffering from primary or secondary insomnia with/without active
             treatment.

          -  Alcoholics as defined by consumption of more than 2 standard alcoholic drinks (more
             than 30 ml/ day) for past 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalini Srivastava, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Vedic Lifesciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vedic Lifesciences Pvt. Ltd</name>
      <address>
        <city>Mumbai</city>
        <state>Opp Infinity Mall</state>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>May 29, 2019</last_update_submitted>
  <last_update_submitted_qc>May 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

